Results 181 to 190 of about 6,669,512 (265)

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network. [PDF]

Hemasphere
Bastos-Oreiro M, Iacoboni G, Navarro V, Martínez C, Manresa P, Magnano L, Jiménez-Ubieto A, Vázquez S, Rodriguez MJ, Busnego MT, Del Campo R, Paúl PJ, Murillo I, Donato EM, Serna A, Luzardo H, Gómez P, Pérez E, Mendibil B, Ramos S, García-Noblejas A, Gonzalez de Villambrosia S, Díaz FJ, López J, Martín-Moro F, Fernandez-Caldas P, Fernandez R, Gutierrez A, Sánchez B, Domínguez N, Civeira M, Villafuerte P, Olazabal I, Zeberio I, Barrenetxea C, Gutierrez N, Romero S, Martín-Consuegra S, Huerga S, Golbano N, Riaza R, Hueso JA, Martinez-Barranco P, Navarro B, Villalón L, Ortega P, Torres A, Ormenazabal I, Sanchez Anton MP, Goñi MA, Abrisqueta P, Martín García-Sancho A.   +51 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

)PNEUMANECTOMY UNDER ACUPUNCTUREANESTHESIA

针刺研究, 1985
Li Zhimin The Second Hospital
doaj  

The AO Spine Upper Cervical Injury Score (UCIS): Development of a Consensus-Based Scoring System Based on Perceived Injury Severity Scores. [PDF]

Global Spine J
Schroeder GD, Dalton J, Ng MK, Schnake K, Bransford R, Chhabra HS, El-Sharkawi M, Bigdon S, Joaquim A, Vaccaro AR, AO Spine Upper Cervical Classification International Validation Members.   +10 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Design and validation of an integrated meta-instrument for nursing assessment in home hospitalization: A study protocol. [PDF]

PLoS One
Barrué-García P, Llagostera-Reverter I, Cervera-Gasch Á, Esteve-Clavero A, Valero-Chillerón MJ, Ortiz-Mallasén V, Aquilué-Ballarín M, Luna-Aleixos D, Sánchez-Galán M, González Chordá VM, VALENF-HAD Group.   +10 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source